

# Northern Health Authority Annual Antibiogram 2026\*

Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Greater than or equal to 80% susceptibility = GOOD CHOICE										Less than 80% susceptibility = POOR CHOICE					
		Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Levofloxacin	Moxifloxacin	Nitrofurantoin
<i>Escherichia coli</i>	4262	89	61	98	87	–	89	92	–	100	93	93	83	74	–	–	96
<i>Citrobacter freundii</i>	84	R	R	R	R	R	R	R	–	98	92	95	89	81	–	–	99
<i>Enterobacter cloacae complex</i> <sup>a</sup>	250	R	R	–	R	–	–	–	–	95	95	93	89	90	–	–	30
<i>Klebsiella aerogenes</i> <sup>b</sup>	78	R	R	–	R	–	–	–	–	100	95	97	99	92	–	–	–
<i>Klebsiella oxytoca</i>	172	93	R	95	65	–	94	97	99	100	99	98	96	97	–	–	86
<i>Klebsiella pneumoniae</i>	499	96	R	97	91	–	93	94	95	100	98	97	94	88	–	–	31
<i>Morganella morganii</i>	68	R	R	–	R	R	–	–	–	100	93	97	88	85	–	–	–
<i>Proteus mirabilis</i>	258	96	83	100	90	–	97	98	–	100	93	90	87	90	–	–	–
<i>Serratia marcescens</i>	53	R	R	–	R	R	–	–	–	98	100	85	98	96	–	–	R
<i>Pseudomonas aeruginosa</i>	378	R	R	88	–	–	–	R	92	90	–	99	R	87	–	–	–
<i>Stenotrophomonas maltophilia</i>	33	R	R	R	–	–	–	R	R	R	–	–	91	–	83	–	–
<i>Haemophilus influenzae</i>	72	80	79	–	–	86	–	100	–	–	–	–	54	–	–	100	–

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend** – Drug not tested or indicated

u Urinary tract infections only

R Intrinsic resistance

<sup>a</sup> Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei

<sup>b</sup> Previously known as Enterobacter aerogenes



10-201-6002 (FF10786-IND-Rev.-03/26)

# Northern Health Authority Annual Antibiogram 2026\*

Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Greater than or equal to 80% susceptibility = GOOD CHOICE										Less than 80% susceptibility = POOR CHOICE					
		Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Levofloxacin	Moxifloxacin	Nitrofurantoin
<i>Escherichia coli</i>	4262	89	61	98	87	–	89	92	–	100	93	93	83	74	–	–	96
<i>Citrobacter freundii</i>	84	R	R	R	R	R	R	R	–	98	92	95	89	81	–	–	99
<i>Enterobacter cloacae complex</i> <sup>a</sup>	250	R	R	–	R	–	–	–	–	95	95	93	89	90	–	–	30
<i>Klebsiella aerogenes</i> <sup>b</sup>	78	R	R	–	R	–	–	–	–	100	95	97	99	92	–	–	–
<i>Klebsiella oxytoca</i>	172	93	R	95	65	–	94	97	99	100	99	98	96	97	–	–	86
<i>Klebsiella pneumoniae</i>	499	96	R	97	91	–	93	94	95	100	98	97	94	88	–	–	31
<i>Morganella morganii</i>	68	R	R	–	R	R	–	–	–	100	93	97	88	85	–	–	–
<i>Proteus mirabilis</i>	258	96	83	100	90	–	97	98	–	100	93	90	87	90	–	–	–
<i>Serratia marcescens</i>	53	R	R	–	R	R	–	–	–	98	100	85	98	96	–	–	R
<i>Pseudomonas aeruginosa</i>	378	R	R	88	–	–	–	R	92	90	–	99	R	87	–	–	–
<i>Stenotrophomonas maltophilia</i>	33	R	R	R	–	–	–	R	R	R	–	–	91	–	83	–	–
<i>Haemophilus influenzae</i>	72	80	79	–	–	86	–	100	–	–	–	–	54	–	–	100	–

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend** – Drug not tested or indicated

u Urinary tract infections only

R Intrinsic resistance

<sup>a</sup> Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei

<sup>b</sup> Previously known as Enterobacter aerogenes



10-201-6002 (FF10786-IND-Rev.-03/26)

# Northern Health Authority Annual Antibiogram 2026\*

Northern Health Authority Gram Positive Organisms % Susceptible	Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
	# of isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin <sup>A</sup>	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin <sup>U</sup>	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2373	–	–	76	–	76	–	75	86	–	–	–	90	95	–	100	–
<i>S. aureus (MRSA)</i> ‡	542	R	R	R	R	R	R	R	86	–	–	–	85	89	–	100	100
<i>Staphylococcus epidermidis</i>	280	–	–	52	–	52	–	50	75	–	–	–	75	87	–	100	–
<i>Staphylococcus lugdunensis</i>	132	–	–	90	–	90	–	93	95	–	–	–	100	97	–	100	100
<i>Enterococcus faecalis</i>	549	99 <sup>B</sup>	99	R	–	–	R	R	R	84	–	81	–	–	99	98	–
<i>Enterococcus faecium</i>	126	R	R	R	–	–	R	R	R	15	–	63	–	–	–	60 <sup>‡</sup>	98
Group A <i>Streptococcus</i>	618	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100	71	72	–	–	–	R	–	–	95	–
Group B <i>Streptococcus</i>	249	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	59	32	–	–	–	R	–	–	100	–
Group C <i>Streptococcus</i>	117	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	81	78	–	–	–	R	–	–	100	–
Group G <i>Streptococcus</i>	150	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	76	77	–	–	–	R	–	–	100	–
<i>Streptococcus pneumoniae</i>	70	99	–	–	100 <sup>2</sup>	–	100 <sup>2</sup>	71	–	–	100	–	75	–	–	100	–
					68 <sup>3</sup>		91 <sup>3</sup>										

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend**

- Drug not tested or indicated
- <sup>U</sup> Urinary tract infections only
- <sup>A</sup> Extrapolated from Cloxacillin
- <sup>S</sup> AST method not validated for this organism/antibiotic combination
- R** Intrinsic resistance
- <sup>B</sup> Extrapolated from Ampicillin
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- <sup>2</sup> Non-meningitis
- <sup>C</sup> Extrapolated from Penicillin
- ‡ Represents clinical isolates – excludes colonization
- <sup>3</sup> Meningitis

\* Prepared by Ally King, Regional Program Lead, Microbiology, based on 2025 NHA cumulative AST data from Jan. 1 2025 to Dec. 31 2025, As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition

# Northern Health Authority Annual Antibiogram 2026\*

Northern Health Authority Gram Positive Organisms % Susceptible	Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
	# of isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin <sup>A</sup>	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin <sup>U</sup>	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2373	–	–	76	–	76	–	75	86	–	–	–	90	95	–	100	–
<i>S. aureus (MRSA)</i> ‡	542	R	R	R	R	R	R	R	86	–	–	–	85	89	–	100	100
<i>Staphylococcus epidermidis</i>	280	–	–	52	–	52	–	50	75	–	–	–	75	87	–	100	–
<i>Staphylococcus lugdunensis</i>	132	–	–	90	–	90	–	93	95	–	–	–	100	97	–	100	100
<i>Enterococcus faecalis</i>	549	99 <sup>B</sup>	99	R	–	–	R	R	R	84	–	81	–	–	99	98	–
<i>Enterococcus faecium</i>	126	R	R	R	–	–	R	R	R	15	–	63	–	–	–	60 <sup>‡</sup>	98
Group A <i>Streptococcus</i>	618	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100	71	72	–	–	–	R	–	–	95	–
Group B <i>Streptococcus</i>	249	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	59	32	–	–	–	R	–	–	100	–
Group C <i>Streptococcus</i>	117	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	81	78	–	–	–	R	–	–	100	–
Group G <i>Streptococcus</i>	150	100 <sup>C</sup>	100 <sup>C</sup>	–	100	–	100 <sup>S</sup>	76	77	–	–	–	R	–	–	100	–
<i>Streptococcus pneumoniae</i>	70	99	–	–	100 <sup>2</sup>	–	100 <sup>2</sup>	71	–	–	100	–	75	–	–	100	–
					68 <sup>3</sup>		91 <sup>3</sup>										

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend**

- Drug not tested or indicated
- <sup>U</sup> Urinary tract infections only
- <sup>A</sup> Extrapolated from Cloxacillin
- <sup>S</sup> AST method not validated for this organism/antibiotic combination
- R** Intrinsic resistance
- <sup>B</sup> Extrapolated from Ampicillin
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- <sup>2</sup> Non-meningitis
- <sup>C</sup> Extrapolated from Penicillin
- ‡ Represents clinical isolates – excludes colonization
- <sup>3</sup> Meningitis

\* Prepared by Ally King, Regional Program Lead, Microbiology, based on 2025 NHA cumulative AST data from Jan. 1 2025 to Dec. 31 2025, As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition